Advertisement

Chinese Science Bulletin

, Volume 47, Issue 1, pp 44–47 | Cite as

Transforming growth factorβ1 and epidermal growth factor decrease the expression of 17β-hydroxysteroid dehydrogenase type 2 in endometrial carcinoma cells

  • Xiaohong Li
  • Zhijie Xiao
  • Yunshang Piao
Notes
  • 5 Downloads

Abstract

Estradiol (E2) is the major molecular form of estrogens. Its biological effects are determined by estrogen receptors and intracellular E2 concentration in target cells. Regulation of intracellular E2 concentration involves the action of 17β-hydroxysteroid dehydrogenase (17HSD) type 2, the enzyme inactivating E2 to estrone. It has been demonstrated that 17HSD type 2 is expressed in normal endometrial epithelia and emdometrial carcinoma cells (RL 95-2). However, the regulatory mechanism of 17HSD type 2 expression in emdometrial cancer cells remains unknown. In the present study, the effects of transforming growth factor-β1 (TGF-β1) and epidermal growth factor (EGF) on 17HSD type 2 expression in RL 95-2 cells have been investigated using enzyme activity assay and Northern blot analysis. After stimulation with TGF-β1 or EGF, the in vivo oxidative 17HSD activity in RL 95-2 cells was significantly decreased. It appeared that the inhibitory effect of TGF-β1 and EGF on the enzyme activity of 17HSD type 2 is dose-and time-dependent. Northern blot analysis further revealed that treatment of cells for 48 h with 10 ng/mL TGF-1 β and 50 ng/mL EGF reduced the expression 17HSD type 2 mRNA to 30% and 20% of the control level, respectively. The data demonstrate that 17HSD type 2 expression in endometrial carcinoma cells is down-regulated by certain growth factors.

Keywords

endometrium estrogen 17β-hydroxysteroid dehydrogenase growth factor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Labrie, F., Intracrinology, Mol. Cell Endocrinol., 1991, 78: C113.CrossRefGoogle Scholar
  2. 2.
    Peltoketo, H., Luu-The, V., Simard, J. et al., 17 β-hydroxysteroid dehydrogenase/17-ketosteroid reductase family: nomenclature and main characteristics of the 17HSD/KSR enzymes, J. Mol. Endocrinol., 1999, 23: 1.CrossRefGoogle Scholar
  3. 3.
    Miettinen, M. M., Mustonen, M. V. J., Poutanen, M. H. et al., Human 17 β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic celland tissue-specific expression, Biochem. J., 1996, 314: 839.Google Scholar
  4. 4.
    Mustonen, M. V. J., Isomaa, V. V., Tommi, V. et al., Human 17 β-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle, J. Clin. Endocrinol. Metab, 1998, 83: 1319.CrossRefGoogle Scholar
  5. 5.
    Sutton, G., Hormonal aspects of endometrial cancer, Current Opin. Obstet Gynecol., 1990, 2: 69.Google Scholar
  6. 6.
    King, R. J. B., Biology of female sex hormone action in relation to contraceptive agents and neoplasia, Contraception, 1991, 43: 527.CrossRefGoogle Scholar
  7. 7.
    Mäentausta, O., Svalander, P., Gemzell, D. K. et al., Immunohistochemical localization of 17 β-hydroxysteroid dehydrogenase (17HSD) in the human endometrium during the menstrual cycle, Lab Invest., 1991, 65: 582.Google Scholar
  8. 8.
    Casey, M. L., MacDonald, P. C., Andersson, S., 17 β-hydroxysteroid dehydrogenase type 2: Chromosomal assignment and progestin regulation of gene expression in human endometrium, J. Clin. Invest., 1994, 94: 2135.CrossRefGoogle Scholar
  9. 9.
    Tseng, L., Gurpide, E., Changes in vitro metabolism of estradiol by human endometrium during the menstrual cycle, Am. J. Obstet. Gynecol., 1972, 114: 1002.Google Scholar
  10. 10.
    Way, D. L., Grosso, D. S., Davis, J. R. et al., Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture, In vitro, 1983, 19: 147.CrossRefGoogle Scholar
  11. 11.
    Piao, Y. S., Peltoketo, H., Jouppila, A. et al., Retinoic acids increase 17 β-hydroxysteroid dehydrogenase type 1 expression in JEG-3 and T47D cells, but the stimulation is potentiated by epidermal growth factor, 12-O-tetradecanoulphorbol-13-acetate, and cyclic adenosine 3′, 5′-monophosphate only in JEG-3 cells, Endocrinology, 1997, 138: 898.CrossRefGoogle Scholar
  12. 12.
    Leake, R., Carr, L., Rinaldi, F., Autocrine and paracrine effects in the endometrium, Ann. NYAcad. Sci., 1991, 622: 145.CrossRefGoogle Scholar
  13. 13.
    Smith, S. K., Growth factors in the human endometrium, Hum. Reprod., 1994, 9: 936.Google Scholar
  14. 14.
    Jantus-Lewintre, E., Orava, M., Vihko, R., Regulation of 17β-hydroxysteroid dehydrogenase type 1 by epidermal growth factor and transforming growth factor alpha in choriocarcinoma cells, Endocrinology, 1994, 135: 2629.CrossRefGoogle Scholar
  15. 15.
    Mäentausta, O., Boman, K., Isomma, V. et al., Immunohistochemical study of the human 17β-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma, Cancer, 1992, 70: 1551.CrossRefGoogle Scholar

Copyright information

© Science in China Press 2002

Authors and Affiliations

  1. 1.State Key Laboratory of Reproductive Biology, Institute of ZoologyChinese Academy of SciencesBeijingChina

Personalised recommendations